Business
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively
About this update from Alector, Inc.
[{"type":"text","content":"Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively\nSOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The events will include presentations from Alector’s management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer’s disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases. Details of the webinars are as follows: Diving Deep into TREM2: Uncovering its Potential as a Therapeutic Target for Alzheimer’s Disease December 7, 2023, from 12:00 pm - 1:30 pm Eastern Standard Time (EST) Alector’s management team will be joined by: Michael Heneka, M.D., Director of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and Adjunct Professor at the University of Massachusetts Chan Medical School Reisa Sperling, M.D., Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital and Massachusetts General Hospital A Detailed Review of PGRN: A Pivotal Stage Program for Frontotemporal Dementia with Broad Additional Opportunities Including Alzheimer’s Disease December 13, 2023, from 11:00 am - 12:30 pm EST Alector’s management team will be joined by: Fenghua Hu, Ph.D., Associate Professor, Department of Molecular Biology and Genetics and Weill Institute for Cell and Molecular Biology at Cornell UniversityAdam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco A live question and answer session will follow the formal presentations. To access the live webcasts of these events, please register here for TREM2 and here for PGRN, or visit “Events and Presentations” in the “Investors” section of the Alector website at https://investors.alector.com. An archived replay...